Skip to main content Accessibility help
×
Home
Hostname: page-component-78bd46657c-9sqjz Total loading time: 0.404 Render date: 2021-05-08T23:33:18.444Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders

Published online by Cambridge University Press:  05 April 2012

E. Paul Cherniack
Affiliation:
Division of Geriatrics and Gerontology, Geriatrics Institute, Geriatrics and Extended Care Service and Geriatric Research Education, and Clinical Center (GRECC) of the Miami Veterans Affairs Medical Center, University of Miami Miller School of Medicine, Room 1D200, 1201 NW 16th Street, Miami, FL 33125, USA
Corresponding
E-mail address:
Rights & Permissions[Opens in a new window]

Abstract

Today, tens of millions of elderly individuals worldwide suffer from dementia. While the pathogenesis of dementia is complex and incompletely understood, it may be, at least to a certain extent, the consequence of systemic vascular pathology. The metabolic syndrome and its individual components induce a proinflammatory state that damages blood vessels. This condition of chronic inflammation may damage the vasculature of the brain or be directly neurotoxic. Associations have been established between the metabolic syndrome, its constituents and dementia. A relationship has also been observed between certain dietary factors, such as constituents of the ‘Mediterranean diet’, and the metabolic syndrome; similar associations have been noted between these dietary factors and dementia. Fruit juices and extracts are under investigation as treatments for cognitive impairment. Blueberry, strawberry, blackberry, grape and plum juices or extracts have been successfully tested in cognitively impaired rodents. Published trials of the benefits of grape and blueberry juice in the treatment of small numbers of cognitively impaired persons have recently appeared. The benefits of fruit products are thought to be a result of its polyphenol content. A grape polyphenol found in grapes, resveratrol, now being studied in humans, and one in grapes and blueberries, pterostilbene, have been found to improve cognition in rodents. In the design of future human trials, one ought to consider the poor bioavailability of these products, the possible need to initiate the experimental therapy long before the onset of symptoms, and currently limited knowledge about the appropriate form (e.g. juice, powder or individual polyphenol) of treatment.

Type
Review Article
Copyright
Copyright © The Author (2012). This is a work of the U.S. Government and is not subject to copyright protection in the United States.

The pathogenesis of dementia and nutrition

While slowing of cognition and some short-term memory loss occur with normal ageing, there is also an increase in a pathological cognitive condition, dementia, with age(Reference Christensen1, Reference Anstey and Low2). The condition affects globally over 35 million people, and will more than triple in the USA in the next four decades(Reference Querfurth and LaFerla3). Dementia is defined by its symptomatology. Demented patients have chronic functional difficulty with memory, in addition to one of the following abnormalities: deficits in executive function (problem-solving, organising a plan to carry out a multi-step activity), agnosia (naming people or objects), aphasia (perception) or apraxia (executing speech or movement)(Reference Kelley and Petersen4Reference Riddle6). Those with some cognitive impairment but that does not meet the definition of ‘dementia’ are considered to have ‘mild cognitive impairment’(Reference Kelley and Petersen4).

The most common form of dementia, which occurs in more than half of all cases, is Alzheimer's disease, which is characterised pathologically by amyloid plaques and neurofibrillary tangles(Reference Querfurth and LaFerla3). A significant minority of cases of dementia, having radiological evidence of infarction, can be referred to as having vascular or multi-infarct dementia. However, vascular pathology may also be present in Alzheimer's disease, and the term ‘mixed dementia’ is sometimes referred to patients who have features of both Alzheimer's and vascular dementia(Reference Dickstein, Walsh and Brautigam7). Together, these conditions account for more than 80 % of all cases of dementia. Parkinson's disease and alcohol are the other causes of dementia; and rarer dementias also have their distinctive pathologies.

The pathogenesis of Alzheimer's disease is a complex, much studied, but yet incompletely understood topic, the totality of which cannot be addressed fully in this paper. Abnormal processing of amyloid peptides whose function is not well understood, occurs as a result of both genetic and other factors, in which mitochondrial failure, formation of neurofibrillary tangles involving mutations of the tau protein, and reduction of the number of synapses in the hippocampus are all involved(Reference Querfurth and LaFerla3). Defective epigenetic DNA repair has also been implicated(Reference Mastroeni, McKee and Grover8Reference Wang, Oelze and Schumacher10).

The effect of vascular disease on the brain may contribute to at least some of these pathological processes. Vascular pathology is present in autopsy specimens of 60–90 % of all patients with Alzheimer's disease(Reference Querfurth and LaFerla3). As previously mentioned, Alzheimer's disease and vascular dementia can coexist.

A proinflammatory state, which is characteristic of the metabolic syndrome (a syndrome defined by central adiposity and two or more of the following: (1) high fasting plasma glucose, (2) low-HDL cholesterol, (3) high blood pressure or (4) high TAG)(Reference Ford11), has also been found to be related to dementia and systemic vascular disease(Reference Frisardi, Solfrizzi and Seripa12, Reference Obunai, Jani and Dangas13). Individual components of the metabolic syndrome – hypertension, hyperlipidaemia, diabetes and high BMI – have also been associated with the incidence of dementia(Reference Frisardi, Solfrizzi and Seripa12). Amyloid precursor protein, a protein whose misprocessing is one of the important neuronal cellular abnormalities observed in Alzheimer's disease, is itself a proinflammatory cytokine that is also present in adipocytes(Reference Frisardi, Solfrizzi and Seripa12). There is a relationship between the production of amyloid precursor protein and other proinflammatory cytokines, such as IL-1β, IL-6 and IL-8(Reference Frisardi, Solfrizzi and Seripa12).

Dietary factors may be related to the development of the metabolic syndrome. Persons who consume a ‘Mediterranean-style diet’, less fat, especially saturated fat, meat, and more fruits and vegetables, are less likely to develop this condition(Reference Rumawas, Meigs and Dwyer14). Both animal and human investigations of the roles of individual components of this diet show that many of its constituents, such as plant polyphenols, may have a beneficial effect on the components of the metabolic syndrome(Reference Abete, Astrup and Martinez15Reference Cefalu and Brantley20, Reference Sivaprakasapillai, Edirisinghe and Randolph21). Among these, berry polyphenols are under active study as treatments. Grape seed compounds prevent the differentiation of adipocytes in vitro, lower blood pressure in humans and reduce ischaemic damage in animal models of myocardial infarction(Reference Sivaprakasapillai, Edirisinghe and Randolph21Reference Nassiri-Asl and Hosseinzadeh23). Resveratrol, a polyphenol found in numerous fruits including grapes, is being currently investigated as a treatment for the metabolic syndrome in a clinical trial(24, 25).

Much research has also suggested a relationship between nutrition and dementia. Several epidemiological studies have implied an association between fruits and vegetables and dementia(Reference Gu, Nieves and Stern26, Reference Barberger-Gateau, Raffaitin and Letenneur27). One investigation found a relationship between consumption of a variety of foods: fruits, dark, green leafy and cruciferous vegetables, tomatoes, fish, nuts, poultry and salad dressings, with Alzheimer's disease(Reference Gu, Nieves and Stern26). Closer adherence to a Mediterranean diet was also correlated with a lowered risk of dementia(Reference Liebson28).

Polyphenols and their mechanism of action on cognitive illness

Polyphenols are being considered as a potential treatment or preventive agent for dementia. Polyphenols may have multiple physiological effects that serve to protect the brain from the pathogenic mechanism underlying dementia. One effect may be a systemic anti-inflammatory action (Fig. 1). Polyphenols retard systemic vascular inflammation by reducing the production of adipocyte-generated inflammatory cytokines through the regulation of adipocyte development. More than fifteen polyphenols have been found to regulate the adipocyte lifecycle, causing anti-proliferative changes such as preventing adipocyte maturation, retarding lipid storage and inducing adipocyte apoptosis(Reference Rayalam, Della-Fera and Baile29). The best-studied fruit polyphenol, resveratrol, interacts at the cellular level with a gene called Sirtuin 1 (SIRT1)(Reference Borra, Smith and Denu30). Activation of SIRT1 heightens insulin release and sensitivity, and promotes the differentiation of many types of cells, but arrests the development of adipocytes(Reference Cacciapuoti31).

Fig. 1 Potential mechanisms for polyphenol activity against dementing illness.

Several polyphenols, including resveratrol and quercetin, lower inflammatory cytokine levels, improve insulin sensitivity and glucose and insulin levels, and reduce blood pressure in animal models and preliminary human trials(Reference Cherniack32). In one investigation, mice that ingested a high-fructose diet and high-cholesterol diet with added resveratrol had a heightened glucose tolerance, insulin sensitivity and lower cholesterol than mice that did not consume resveratrol(Reference Deng and Hung33). In another study on mice, rodents that ingested resveratrol had lower amounts of visceral fat, and reduced levels of glucose, TAG, cholesterol, and the inflammatory cytokines monocyte chemotactic protein-1 (MCP-1) and TNF-α(Reference Kim, Jin and Choi34). Rats consuming resveratrol for 4 weeks had decreased levels of lipids and serum glucose(Reference Rocha, Souza and Ebaid35). In a study, ten overweight older subjects (average age of 72 years) with reduced glucose tolerance who ingested resveratrol for 4 weeks augmented their insulin sensitivity(Reference Crandall and Oram36).

Quercetin is another polyphenol with anti-inflammatory activity. The polyphenol reduces the output of the proinflammatory cytokines IL-8 and TNF-α in vitro (Reference Boots, Haenen and Bast37). Individuals with the metabolic syndrome who consumed quercetin achieved small reductions in blood pressure(Reference Egert, Bosy-Westphal and Seiberl38).

Polyphenols may be beneficial in the treatment of cognitive disorders by protecting the brain vasculature against the proinflammatory state induced by the metabolic syndrome. Diabetic rats that received resveratrol showed a significantly better performance on memory tests (rats were placed in a device where they learned to avoid foot shocks) than those that received a placebo(Reference Schmatz, Mazzanti and Spanevello39).

Polyphenols, especially cocoa flavonols, may also preserve cognition by causing other beneficial changes in the cerebral vasculature (Fig. 1). These include enhancing cerebral blood flow, local endothelial repair mechanisms, and retarding platelet aggregation and augmenting vasodilation through increasing nitric oxide levels(Reference Williams and Spencer40). Resveratrol promotes the production of nitrous oxide(Reference Cacciapuoti31). This preservation of the cerebral vasculature may allow the maintenance of hippocampal neurons, the loss of which may be an important feature in dementing illness(Reference Williams and Spencer40).

In addition, polyphenols may have direct neuroprotective effects on neurons. Resveratrol averts neuronal loss in several animal models in which neurons are exposed to toxic agents.

Resveratrol protected mouse neurons in vitro when exposed to toxins(Reference Sakata, Zhuang and Kwansa41). In newborn rats, resveratrol reduced neuronal loss after traumatic brain injury(Reference Sonmez, Sonmez and Erbil42). Rats with dementia caused through injections of streptozocin had improved memory and learning (tested by maze negotiation and avoidance of foot shocks) after being given resveratrol(Reference Sharma and Gupta43). In another rat dementia model, in which rats were injected with colchicine, resveratrol again alleviated the deficit in cognitive function measured by the water maze test(Reference Kumar, Naidu and Seghal44). Elderly rats fed pterostilbene, another polyphenol found in grapes and blueberries. had better performances on the water maze test than those fed a control substance, and pterostilbene provided even greater in vitro protection in a chemical-induced neurotoxicity model than resveratrol(Reference Cherniack32).

While the mechanism of this neuroprotective effect has not been fully elucidated, there are many possible hypotheses. Polyphenols activate the neurotransmitter on neurons that facilitate neuronal and microglial growth gene pathways(Reference Williams and Spencer40). A polyphenol subtype, flavonoids, which include resveratrol, quercertin and epigallocathechin gallate, in animal models modulate the synthesis, processing and disposal of amyloid peptides that may be important in the pathogenesis of dementia(Reference Williams and Spencer40).

Polyphenols may induce epigenetic changes that are neuroprotective (Fig. 1). Histone acetylation may be implicated in the pathogenesis of several dementing illnesses, including Alzheimer's disease and Parkinson's disease(Reference Stilling and Fischer45, Reference Iraola-Guzman, Estivill and Rabionet46). SIRT1, which may be a target of resveratrol action, also codes for an enzyme known as histone deacetylase(Reference Huber, McBurney and Distefano47). This enzyme causes conformational changes in histones about which DNA is wrapped, that reveal the DNA to prepare it for transcription by RNA polymerases(Reference Sweatt48). Mice engineered with a defect in histone acetylation show greater memory deficits in old age(Reference Peleg, Sananbenesi and Zovoilis49).

Clinical trials on the use of resveratrol in combination with other substances in the treatment of dementia are now underway. At the Bronx, New York, United States Department of Veterans Affairs Medical Center, an investigation is underway in which sixty subjects with Alzheimer's disease are being given grape juice supplemented with resveratrol, malate and glucose, or a placebo drink for 1 year(50). At the Medical College of Wisconsin, another placebo-controlled trial is taking place in which fifty subjects with Alzheimer's disease are taking one 215 mg tablet a day for 1 year of Longevinex, a dietary supplement that contains resveratrol, quercetin (another grape polyphenol), rice bran, ferulic acid and 1200 IU of vitamin D3 (51).

Fruit juices and extracts

Polyphenols occur naturally in fruits and plants, which can be synthesised into fruit juices and extracts. The polyphenols in these compounds may act individually or synergistically to protect cognition through the same mechanisms as do individual polyphenols.

Consumption of fruit extracts and juices may preserve neurons and improve cognition in aged rodents(Reference Shukitt-Hale, Lau and Joseph52, Reference Joseph, Shukitt-Hale and Willis53). Blueberry products are among the most well-studied in this context. Blueberry supplements increase the levels of neuroprotective heat shock proteins in aged rats(Reference Galli, Bielinski and Szprengiel54). In a study, 6-month-old (young) rats that were fed blueberry extracts for 8 months (until old age) had better performances on a water maze test (a test of recall and spatial learning in which rats are placed in water and given cues to find a hidden platform to allow it to leave the water)(Reference Joseph, Fisher and Cheng55) than those fed a placebo(Reference Joseph, Shukitt-Hale and Denisova56). Addition of a blueberry supplement to 15-month-old (elderly) rats significantly enhanced their ability on an object recognition test(Reference Goyarzu, Malin and Lau57). In another trial, old rats that ate a blueberry extract for 2 months had significantly better balanced walking across a wire or rotating rod and negotiated the water maze more quickly than at baseline, which control rats fed a placebo supplement did not(Reference Joseph, Shukitt-Hale and Denisova58). However, in a similar trial in which the rats were given a blueberry supplement for an extra month, the rodents demonstrated improved motor function as demonstrated by the ability to hang on to a tilted screen, but did not have improved cognitive function in water maze tests(Reference Shukitt-Hale, Galli and Meterko59). Rats that had cognitive impairment induced by injection of a neurotoxic agent (kainic acid) and consumed over 2 months a blueberry extract had a better maze performance than those that did not(Reference Duffy, Spangler and Devan60). When transgenic mice engineered to create an Alzheimer's disease model of dementia were given a blueberry supplement, they maintained better coordination, strength, muscle tone and balance, but did not have fewer amyloid plaques in their brains(Reference Joseph, Denisova and Arendash61). Blueberry extracts also preserved neurogenesis in the hippocampus of elderly rats(Reference Casadesus, Shukitt-Hale and Stellwagen62).

An investigation of the benefit of blueberry juice in the treatment of people with cognitive impairment has been published(Reference Krikorian, Shidler and Nash63). A total of nine subjects, mean age 76·2, drank 6–9 ml/kg of commercially manufactured blueberry juice a day for 3 months. In the study, seven other subjects consumed a placebo drink. At the end of 3 months, those who consumed blueberry juice had a 41 % improvement on the Verbal Paired Associate Learning Test (a test of the associations between two unrelated words, 13·2 v. 9·3 on a 0-to-20 word pair scoring scale; P = 0·009) and a 33 % improvement on the California Verbal Learning Test (a test of list learning and recall, 9·6 v. 7·2 on a 0-to-16 word scoring scale; P = 0·04). In addition, on the Verbal Paired Associate Learning Test, those who consumed blueberry juice had 86 % higher scores as compared to those who consumed the placebo drink (13 v. 7; P = 0·03), but there was not a significant difference between groups in scores on the California Verbal Learning Test.

Grape products are also being actively investigated. Grape seed extract has been observed to increase antioxidant enzyme levels in rodent brains(Reference Devi, Jolitha and Ishii64). Mixtures of grape polyphenols inhibit the formation of amyloid plaques in mouse dementia models(Reference Ono, Condron and Ho65, Reference Wang, Ho and Zhao66). Young mice genetically engineered to become demented that consumed a grape polyphenol extract performed better on the water maze test than those given water instead(Reference Wang, Ho and Zhao66).

The first published human trial showing the benefit of a grape-derived product on cognition was recently published. In this trial, twelve subjects with mild cognitive impairment drank 6–9 ml/kg of Concord grape juice or a placebo for 3 months(Reference Krikorian, Nash and Shidler67). Subjects who drank grape juice had a 20 % improvement in their score (38 v. 33 items) on a 44-item California Verbal Learning Test (P = 0·04) from baseline.

At the University of Oslo, Norway, a trial has recently been completed in which elderly individuals who are not demented but had a ‘gradual subjective memory decline’ were given 9 weeks of a 50 % bilberry (European blueberry), 50 % red grape juice mixture in a double-blinded, placebo-controlled trial(68). The results of the trial have not yet appeared in print.

Other fruit juices have improved cognition in animal models, and some have been used in human trials. In a previously mentioned trial which included a blueberry extract, a strawberry supplement also enhanced rats' speed at completing a water maze and ability to cross a wire(Reference Joseph, Shukitt-Hale and Denisova58). In another trial involving blueberry juice, a cranberry extract enhanced the ability of rats to cling to a wire, but did not affect cognition(Reference Shukitt-Hale, Galli and Meterko59). In a study, fifty normal elderly individuals drank 32 ounces a day of a drink containing 27 % cranberry juice or a placebo(Reference Crews, Harrison and Griffin69). However, there were no differences in neuropsychological testing between subjects in the two groups at the end of this 6-week study. Elderly rats that drank blackberry juice completed the water maze test in less time and were able to balance on a rotating rod for longer than those given a placebo(Reference Shukitt-Hale, Cheng and Joseph70). Old rats that drank plum juice for 2 months negotiated the water maze more quickly, but those that consumed a plum powder had no benefit(Reference Shukitt-Hale, Kalt and Carey71). Apple juice prevented cognitive impairment and increased amyloid-β in aged mice caused by dietary folate or apoE deficiency(Reference Tchantchou, Chan and Kifle72Reference Chan and Shea74). In an open-label trial, twenty-one elderly persons with Alzheimer's disease drank two four-ounce glasses of apple juice daily for 30 d. The institutional caregivers of these subjects described a 27 % improvement in behavioural symptoms, although there was no change in cognition(Reference Remington, Chan and Lepore75).

Future considerations

Thus far, the research on the use of fruit polyphenols in the treatment of cognitive impairment appears promising. However, there are many further considerations that need to be addressed in the design of more definitive studies.

First, one important consideration is the optimum age for the initiation of therapy. The pathogenic progress resulting in dementia, which might be the consequence of a systemic inflammatory process on the vasculature, might occur years before the onset of symptoms. If this is the case, the optimum time for the initiation of therapy might be in young or middle age, long before symptoms occur. In rodent trials, starting treatments in middle age, which might occur after more than a year in a 2-year lifespan, is not a great difficulty. However, in a human trial, one might have to give the supplement for decades to observe the optimum effect, making the study unfeasible.

In addition, the bioavailability of polyphenols consumed from supplements has been called into question(Reference Scalbert and Williamson76Reference Rossi, Mazzitelli and Arciello78). The bioavailability of most polyphenols, especially those of higher molecular weight is quite limited(Reference Scalbert and Williamson76, Reference Bravo77, Reference Del Rio, Borges and Crozier79Reference Cottart, Nivet-Antoine and Laguillier-Morizot82). They are poorly absorbed and extensively metabolised first in the intestine, where they are conjugated through glucuronidation, methylation or sulphation(Reference Manach, Williamson and Morand81). They are then transported to the liver, where they undergo further metabolism(Reference Manach, Williamson and Morand81). Finally, they are readily excreted in the urine or in the bile, resulting in low serum levels for most polyphenols(Reference Del Rio, Borges and Crozier79, Reference Manach, Williamson and Morand81, Reference Cottart, Nivet-Antoine and Laguillier-Morizot82). Pharmacokinetic studies in humans have confirmed this pattern for resveratrol and quercetin, which have been analysed both in single- and multiple-dose administration. However, many of the investigation of the bioavailability of other polyphenols have relied upon the ingestion of single doses of substances. There is controversy involving the accuracy of the assays used to detect the levels of polyphenols and their metabolites, resulting in additional uncertainty about possible error(Reference Del Rio, Borges and Crozier79, Reference Crozier, Del Rio and Clifford80). Studies of resveratrol pharmacokinetics may have underestimated serum resveratrol plasma levels due to technical problems in quantification(Reference Cottart, Nivet-Antoine and Laguillier-Morizot82).

Furthermore, it is unclear how readily the small quantities that enter the blood stream cross the blood–brain barrier(Reference Rossi, Mazzitelli and Arciello78). If the effect of polyphenols on the brain is primarily mediated through its systemic effect on the vasculature, the latter concern is less important. Furthermore, the concern about bioavailability is based on studies of the pharmacokinetics of certain individual polyphenols, particularly resveratrol, which may be less applicable for other polyphenols and mixtures. In fact, the effects of polyphenols might be mediated through the active metabolites of ingested polyphenols, or through the synergism of multiple polyphenols in a compound, such as that occurring in fruit extracts or juices(Reference Scalbert and Williamson76, Reference Cottart, Nivet-Antoine and Laguillier-Morizot82).

A related consideration is the form in which polyphenols are consumed. Polyphenols may be given naturally as a fruit, processed into juices, extracts and tablets, or given as individual polyphenols. At present, there is not much evidence about which form is the best to administer.

In a previously mentioned study on the effect of plum extract on rat cognition, the greater effect caused by plum juice than plum powder was postulated to be either the result of a greater polyphenol content of the juice, changes in the form, differences in the amounts and bioavailability of different polyphenols, or caused by differences in the manufacture and storing of juice and powder from the fruit(Reference Shukitt-Hale, Kalt and Carey71). Further chemical and pharmacokinetic studies may be necessary to fully resolve these issues.

Acknowledgements

The concept, preparation and writing of this paper were entirely the work of its sole author. There are no conflicts of interest in the publication of this review, nor was any specific grant from any funded agency in the public, commercial or not-for-profit sector used to prepare it.

References

1Christensen, H (2001) What cognitive changes can be expected with normal ageing? Aust N Z J Psychiatry 35, 768775.CrossRefGoogle ScholarPubMed
2Anstey, KJ & Low, LF (2004) Normal cognitive changes in aging. Aust Fam Physician 33, 783787.Google Scholar
3Querfurth, HW & LaFerla, FM (2010) Alzheimer's disease. N Engl J Med 362, 329344.CrossRefGoogle ScholarPubMed
4Kelley, BJ & Petersen, RC (2007) Alzheimer's disease and mild cognitive impairment. Neurol Clin 25, 577609.CrossRefGoogle ScholarPubMed
5Roth, RM, Isquith, PK & Gioia, GA (2005) Executive function: concepts, assessment and intervention. In Psychologists' Desk Reference, 2nd ed., pp. 3841 [Koocher, GP, Norcross, JC and Hill, SS, editors]. New York, NY: Oxford University Press.Google Scholar
6Riddle, DR (2007) Brain Aging: Models, Methods, and Mechanisms. Boca Raton, FL: CRC Press.CrossRefGoogle ScholarPubMed
7Dickstein, DL, Walsh, J, Brautigam, H, et al. (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77, 82102.CrossRefGoogle ScholarPubMed
8Mastroeni, D, McKee, A, Grover, A, et al. (2009) Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 4, e6617.CrossRefGoogle ScholarPubMed
9Graff, J & Mansuy, IM (2009) Epigenetic dysregulation in cognitive disorders. Eur J Neurosci 30, 18.CrossRefGoogle ScholarPubMed
10Wang, SC, Oelze, B & Schumacher, A (2008) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3, e2698.CrossRefGoogle ScholarPubMed
11Ford, ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28, 27452749.CrossRefGoogle ScholarPubMed
12Frisardi, V, Solfrizzi, V, Seripa, D, et al. (2010) Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9, 399417.CrossRefGoogle ScholarPubMed
13Obunai, K, Jani, S & Dangas, GD (2007) Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am 91, 11691184, x.CrossRefGoogle ScholarPubMed
14Rumawas, ME, Meigs, JB, Dwyer, JT, et al. (2009) Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. Am J Clin Nutr 90, 16081614.CrossRefGoogle ScholarPubMed
15Abete, I, Astrup, A, Martinez, JA, et al. (2010) Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr Rev 68, 214231.CrossRefGoogle ScholarPubMed
16Poudyal, H, Campbell, F & Brown, L (2010) Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 140, 946953.CrossRefGoogle ScholarPubMed
17Bose, M, Lambert, JD, Ju, J, et al. (2008) The major green tea polyphenol, ( − )-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 138, 16771683.CrossRefGoogle ScholarPubMed
18Brown, AL, Lane, J, Coverly, J, et al. (2009) Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr 101, 886894.CrossRefGoogle ScholarPubMed
19Camargo, A, Ruano, J, Fernandez, JM, et al. (2010) Gene expression changes in mononuclear cells from patients with metabolic syndrome after acute intake of phenol-rich virgin olive oil. BMC Genomics 11, 253.CrossRefGoogle ScholarPubMed
20Cefalu, WT & Brantley, PJ (2008) Botanicals and cardiometabolic risk: positioning science to address the hype. Metabolism 57, S1S2.CrossRefGoogle ScholarPubMed
21Sivaprakasapillai, B, Edirisinghe, I, Randolph, J, et al. (2009) Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism 58, 17431746.CrossRefGoogle ScholarPubMed
22Pinent, M, Blade, MC, Salvado, MJ, et al. (2005) Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation. Int J Obes (Lond) 29, 934941.CrossRefGoogle Scholar
23Nassiri-Asl, M & Hosseinzadeh, H (2009) Review of the pharmacological effects of Vitis vinifera (grape) and its bioactive compounds. Phytother Res 23, 11971204.CrossRefGoogle ScholarPubMed
24National Institutes of Health, Clinical Trials.gov (2010) Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome (RSV). http://www.clinicaltrials.gov/ct2/show/NCT00654667?term = resveratrol+metabolic+syndrome&rank = 1 (accessed 13 May 2010).Google Scholar
25National Institutes of Health, Clinical Trials.gov (2010) Effect of Resvida, a Comparison With Calorie Restriction Regimen. http://clinicaltrials.gov/ct2/show/NCT00823381?term=resvida&rank=1 (accessed 13 May 2010).Google Scholar
26Gu, Y, Nieves, JW, Stern, Y, et al. (2010) Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 67, 699706.CrossRefGoogle ScholarPubMed
27Barberger-Gateau, P, Raffaitin, C, Letenneur, L, et al. (2007) Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 69, 19211930.CrossRefGoogle ScholarPubMed
28Liebson, PR (2010) Diet, lifestyle, and hypertension and mediterranean diet and risk of dementia. Prev Cardiol 13, 9496.CrossRefGoogle Scholar
29Rayalam, S, Della-Fera, MA & Baile, CA (2008) Phytochemicals and regulation of the adipocyte life cycle. J Nutr Biochem 19, 717726.CrossRefGoogle ScholarPubMed
30Borra, MT, Smith, BC & Denu, JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280, 1718717195.CrossRefGoogle ScholarPubMed
31Cacciapuoti, F (2008) Opposite effects of metabolic syndrome and calorie restriction on thrombotic disease: head and tail of same coin–resveratrol's role. Metab Syndr Relat Disord 7, 397400.CrossRefGoogle Scholar
32Cherniack, EP (2011) Polyphenols: planting the seeds of treatment for the metabolic syndrome running head: plant polyphenols and the metabolic syndrome. Nutrition 27, 617623.CrossRefGoogle Scholar
33Deng, J-Y & Hung, L-M (2005) Resveratrol improves insulin resistance in high cholesterol-fructose diet Induced metabolic syndrome. In 3rd Annual World Congress on the Insulin Resistance Syndrome, San Francisco, CA, USA.Google Scholar
34Kim, S, Jin, Y, Choi, Y, et al. (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81, 13431351.CrossRefGoogle ScholarPubMed
35Rocha, KK, Souza, GA, Ebaid, GX, et al. (2009) Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 47, 13621367.CrossRefGoogle ScholarPubMed
36Crandall, JP, Oram, V, et al. (2010) Resveratrol improves glucose metabolism in older adults with IGT. Abstract #736-P. In American Diabetes Association, 70th Scientific Session, Orlando, FL, USA.Google Scholar
37Boots, AW, Haenen, GR & Bast, A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585, 325337.CrossRefGoogle ScholarPubMed
38Egert, S, Bosy-Westphal, A, Seiberl, J, et al. (2009) Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr 102, 10651074.CrossRefGoogle ScholarPubMed
39Schmatz, R, Mazzanti, CM, Spanevello, R, et al. (2009) Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol 610, 4248.CrossRefGoogle ScholarPubMed
40Williams, RJ & Spencer, JP (2012) Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med 52, 3545.CrossRefGoogle ScholarPubMed
41Sakata, Y, Zhuang, H, Kwansa, H, et al. (2010) Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp Neurol 224, 325329.CrossRefGoogle ScholarPubMed
42Sonmez, U, Sonmez, A, Erbil, G, et al. (2007) Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett 420, 133137.CrossRefGoogle ScholarPubMed
43Sharma, M & Gupta, YK (2002) Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71, 24892498.CrossRefGoogle ScholarPubMed
44Kumar, A, Naidu, PS, Seghal, N, et al. (2007) Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 79, 1726.CrossRefGoogle ScholarPubMed
45Stilling, RM & Fischer, A (2011) The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol Learn Mem 96, 1926.CrossRefGoogle ScholarPubMed
46Iraola-Guzman, S, Estivill, X & Rabionet, R (2011) DNA methylation in neurodegenerative disorders: a missing link between genome and environment? Clin Genet 80, 114.CrossRefGoogle Scholar
47Huber, JL, McBurney, MW, Distefano, PS, et al. (2011) SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem 2, 17511759.CrossRefGoogle Scholar
48Sweatt, JD (2007) Behavioural neuroscience: down memory lane. Nature 447, 151152.CrossRefGoogle ScholarPubMed
49Peleg, S, Sananbenesi, F, Zovoilis, A, et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753756.CrossRefGoogle ScholarPubMed
50National Institutes of Health, Clinical Trials.gov (2010) Randomized Trial of a Nutritional Supplement in Alzheimer's Disease. http://clinicaltrials.gov/ct2/show/NCT00678431?term = randomized+trial+of+a+nutritional+supplement+in+Alzheimer%27s+Disease&rank = 1 (accessed 13 May 2010).Google Scholar
51National Institutes of Health, Clinical Trials.gov (2010) Pilot Study of the Effects of Resveratrol Supplement in Mild-to-Moderate Alzheimer's Disease. http://clinicaltrials.gov/ct2/show/NCT00743743?term = Pilot+Study+of+the+Effects+of+Resveratrol+Supplement&rank = 1 (accessed 13 May 2010).Google Scholar
52Shukitt-Hale, B, Lau, FC & Joseph, JA (2008) Berry fruit supplementation and the aging brain. J Agric Food Chem 56, 636641.CrossRefGoogle ScholarPubMed
53Joseph, JA, Shukitt-Hale, B & Willis, LM (2009) Grape juice, berries, and walnuts affect brain aging and behavior. J Nutr 139, 1813S1817S.CrossRefGoogle ScholarPubMed
54Galli, RL, Bielinski, DF, Szprengiel, A, et al. (2006) Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 neuroprotection. Neurobiol Aging 27, 344350.CrossRefGoogle ScholarPubMed
55Joseph, JA, Fisher, DR, Cheng, V, et al. (2008) Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J Agric Food Chem 56, 1054410551.CrossRefGoogle ScholarPubMed
56Joseph, JA, Shukitt-Hale, B, Denisova, NA, et al. (1998) Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. J Neurosci 18, 80478055.CrossRefGoogle ScholarPubMed
57Goyarzu, P, Malin, DH, Lau, FC, et al. (2004) Blueberry supplemented diet: effects on object recognition memory and nuclear factor-kappa B levels in aged rats. Nutr Neurosci 7, 7583.CrossRefGoogle ScholarPubMed
58Joseph, JA, Shukitt-Hale, B, Denisova, NA, et al. (1999) Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci 19, 81148121.CrossRefGoogle ScholarPubMed
59Shukitt-Hale, B, Galli, RL, Meterko, V, et al. (2005) Dietary supplementation with fruit polyphenolics ameliorates age-related deficits in behavior and neuronal markers of inflammation and oxidative stress. Age 27, 4957.CrossRefGoogle ScholarPubMed
60Duffy, KB, Spangler, EL, Devan, BD, et al. (2008) A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a kainate-induced learning impairment in rats. Neurobiol Aging 29, 16801689.CrossRefGoogle ScholarPubMed
61Joseph, JA, Denisova, NA, Arendash, G, et al. (2003) Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 6, 153162.CrossRefGoogle Scholar
62Casadesus, G, Shukitt-Hale, B, Stellwagen, HM, et al. (2004) Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. Nutr Neurosci 7, 309316.CrossRefGoogle ScholarPubMed
63Krikorian, R, Shidler, MD, Nash, TA, et al. (2010) Blueberry supplementation improves memory in older adults. J Agric Food Chem 58, 39964000.CrossRefGoogle ScholarPubMed
64Devi, A, Jolitha, AB & Ishii, N (2006) Grape seed proanthocyanidin extract (GSPE) and antioxidant defense in the brain of adult rats. Med Sci Monit 12, BR124BR129.Google ScholarPubMed
65Ono, K, Condron, MM, Ho, L, et al. (2008) Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J Biol Chem 283, 3217632187.CrossRefGoogle ScholarPubMed
66Wang, J, Ho, L, Zhao, W, et al. (2008) Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 28, 63886392.CrossRefGoogle Scholar
67Krikorian, R, Nash, TA, Shidler, MD, et al. (2010) Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr 103, 730734.CrossRefGoogle ScholarPubMed
68National Institutes of Health, Clinical Trials.gov (2010) Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters (BLUEBERRY). http://clinicaltrials.gov/ct2/show/NCT00972972?term=bilberry+grape+cognition&rank=1 (accessed 13 May 2010).Google Scholar
69Crews, WD Jr, Harrison, DW, Griffin, ML, et al. (2005) A double-blinded, placebo-controlled, randomized trial of the neuropsychologic efficacy of cranberry juice in a sample of cognitively intact older adults: pilot study findings. J Altern Complement Med 11, 305309.CrossRefGoogle Scholar
70Shukitt-Hale, B, Cheng, V & Joseph, JA (2009) Effects of blackberries on motor and cognitive function in aged rats. Nutr Neurosci 12, 135140.CrossRefGoogle ScholarPubMed
71Shukitt-Hale, B, Kalt, W, Carey, AN, et al. (2009) Plum juice, but not dried plum powder, is effective in mitigating cognitive deficits in aged rats. Nutrition 25, 567573.CrossRefGoogle Scholar
72Tchantchou, F, Chan, A, Kifle, L, et al. (2005) Apple juice concentrate prevents oxidative damage and impaired maze performance in aged mice. J Alzheimers Dis 8, 283287.CrossRefGoogle ScholarPubMed
73Rogers, EJ, Milhalik, S, Ortiz, D, et al. (2004) Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. J Nutr Health Aging 8, 9297.Google ScholarPubMed
74Chan, A & Shea, TB (2009) Dietary supplementation with apple juice decreases endogenous amyloid-beta levels in murine brain. J Alzheimers Dis 16, 167171.CrossRefGoogle ScholarPubMed
75Remington, R, Chan, A, Lepore, A, et al. (2010) Apple juice improved behavioral but not cognitive symptoms in moderate-to-late stage Alzheimer's disease in an open-label pilot study. Am J Alzheimers Dis Other Demen 25, 367371.CrossRefGoogle ScholarPubMed
76Scalbert, A & Williamson, G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130, 2073S2085S.CrossRefGoogle ScholarPubMed
77Bravo, L (1998) Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56, 317333.CrossRefGoogle ScholarPubMed
78Rossi, L, Mazzitelli, S, Arciello, M, et al. (2008) Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res 33, 23902400.CrossRefGoogle ScholarPubMed
79Del Rio, D, Borges, G & Crozier, A (2010) Berry flavonoids and phenolics: bioavailability and evidence of protective effects. Br J Nutr 104, Suppl. 3, S67S90.CrossRefGoogle ScholarPubMed
80Crozier, A, Del Rio, D & Clifford, MN (2010) Bioavailability of dietary flavonoids and phenolic compounds. Mol Aspects Med 31, 446467.CrossRefGoogle ScholarPubMed
81Manach, C, Williamson, G, Morand, C, et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81, 230S242S.CrossRefGoogle ScholarPubMed
82Cottart, CH, Nivet-Antoine, V, Laguillier-Morizot, C, et al. (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54, 716.CrossRefGoogle ScholarPubMed
You have Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *